235 related articles for article (PubMed ID: 34447241)
21. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.
Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H
Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983
[TBL] [Abstract][Full Text] [Related]
22. Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles.
Wang J
Drug Des Devel Ther; 2020; 14():823-832. PubMed ID: 32161442
[TBL] [Abstract][Full Text] [Related]
23. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
Li C; Ge X; Wang L
Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
[TBL] [Abstract][Full Text] [Related]
24. Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.
Liu Y; Zhang H; Cui H; Zhang F; Zhao L; Liu Y; Meng Q
Drug Deliv; 2022 Dec; 29(1):342-350. PubMed ID: 35049388
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
[No Abstract] [Full Text] [Related]
26. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
27. Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Dong Z; Wang Y; Guo J; Tian C; Pan W; Wang H; Yan J
Drug Des Devel Ther; 2022; 16():2683-2693. PubMed ID: 35983428
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin.
Pradhan R; Ramasamy T; Choi JY; Kim JH; Poudel BK; Tak JW; Nukolova N; Choi HG; Yong CS; Kim JO
Carbohydr Polym; 2015 Jun; 123():313-23. PubMed ID: 25843864
[TBL] [Abstract][Full Text] [Related]
30. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Lu Z; Su J; Li Z; Zhan Y; Ye D
Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
[TBL] [Abstract][Full Text] [Related]
32. Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin.
Nan Y
Oncol Rep; 2019 Nov; 42(5):2087-2096. PubMed ID: 31545462
[TBL] [Abstract][Full Text] [Related]
33. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Song S; Chen F; Qi H; Li F; Xin T; Xu J; Ye T; Sheng N; Yang X; Pan W
Pharm Res; 2014 Apr; 31(4):1032-45. PubMed ID: 24154802
[TBL] [Abstract][Full Text] [Related]
34. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer.
Mahira S; Kommineni N; Husain GM; Khan W
Biomed Pharmacother; 2019 Feb; 110():803-817. PubMed ID: 30554119
[TBL] [Abstract][Full Text] [Related]
35. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
Hongo H; Kosaka T; Suzuki Y; Oya M
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983
[TBL] [Abstract][Full Text] [Related]
37. Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system.
Qiu L; Dong C; Kan X
Drug Des Devel Ther; 2018; 12():863-872. PubMed ID: 29713144
[TBL] [Abstract][Full Text] [Related]
38. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
[TBL] [Abstract][Full Text] [Related]
39. Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment.
Mao K; Zhang W; Yu L; Yu Y; Liu H; Zhang X
Drug Des Devel Ther; 2021; 15():3475-3486. PubMed ID: 34413632
[TBL] [Abstract][Full Text] [Related]
40. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Eskra JN; Schlicht MJ; Bosland MC
Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
